Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy-Reference-Cited by-同舟云学术

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

Published:2016-10-15 Issue:47 Volume:7 Page:77404-77415
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Nakamura Yoshio¹²,Kitano Shigehisa³,Takahashi Akira¹,Tsutsumida Arata¹,Namikawa Kenjiro¹,Tanese Keiji²,Abe Takayuki⁴,Funakoshi Takeru²,Yamamoto Noboru³,Amagai Masayuki²,Yamazaki Naoya¹

Affiliation:

1. Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan

2. Department of Dermatology, Keio University School of Medicine, Tokyo, Japan

3. Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan

4. Department of Preventive Medicine and Public Health, Biostatistics Unit at Clinical Translational Research Center, Keio University School of Medicine, Tokyo, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives;Clinical and Translational Radiation Oncology;2024-11

2. Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses;Journal of Gastrointestinal Cancer;2024-07-15

3. The relationship between LDH and GLIM criteria for cancer cachexia: Systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-07

4. Lymphocyte activation markers predict the therapeutic response to immune checkpoint inhibitors: A case–control study;Cancer Medicine;2024-06

5. Efficacy and safety of salvage-line nivolumab monotherapy for advanced esophageal squamous cell carcinoma: Comparison of 240 mg versus 480 mg doses;2024-05-02